Drug Trial Radar · NCT02556788
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Nov 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,212
Actual
Start
Nov 2015
Primary completion
Feb 7, 2017
Study completion May 12, 2017
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
CD5789 (trifarotene) 50µg/g CreamDrug
CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
Placebo CreamDrug
Placebo cream applied once daily during 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)Time frame: From Baseline to Week 12
Locations
81 sites in 8 countries. Site status is shown where the registry gives one.
Galderma Investigational Site
Birmingham, Alabama
Galderma Investigational Site
Phoenix, Arizona
Galderma Investigational Site
Tucson, Arizona
Galderma Investigational Site
Fort Smith, Arkansas
Galderma Investigational Site
Los Angeles, California
Galderma Investigational Site
Murrieta, California
Galderma Investigational Site
Santa Ana, California
Galderma Investigational Site
Aventura, Florida
Galderma Investigational Site
Miami, Florida
Galderma Investigational Site
Miami Lakes, Florida
Galderma Investigational Site
West Palm Beach, Florida
Galderma Investigational Site
Corbin, Kentucky
Galderma Investigational Site
Beverly, Massachusetts
Galderma Investigational Site
Ann Arbor, Michigan
Galderma Investigational Site
Detroit, Michigan
Galderma Investigational Site
Brooklyn, New York
Galderma Investigational Site
Stony Brook, New York
Galderma Investigational Site
Wilmington, North Carolina
Galderma Investigational Site
Fort Washington, Pennsylvania
Galderma Investigational Site
Philadelphia, Pennsylvania
Galderma Investigational Site
Greer, South Carolina
Galderma Investigational Site
Goodlettsville, Tennessee
Galderma Invetsigational site
Austin, Texas
Galderma Investigational Site
Dallas, Texas
Galderma Investigational Site
Houston, Texas
Galderma Investigational Site
Pflugerville, Texas
Galderma Investigational Site
San Antonio, Texas
Galderma Investigational Site
Webster, Texas
Galderma Investigational Site
Walla Walla, Washington
Galderma Investigational Site
Chomutov, Czechia
Galderma Investigational Site
Hradec Králové, Czechia
Galderma Investigational Site
Kutná Hora, Czechia
Galderma Investigational Site
Olomouc, Czechia
Galderma Investigational Site
Pardubice, Czechia
Galderma Investigational Site
Prague, Czechia
Galderma Investigational Site
Prague, Czechia
Galderma Investigational Site
Prague, Czechia
Galderma Investigational Site
Budapest, Hungary
Galderma Investigational Site
Budapest, Hungary
Galderma Investigational Site
Debrecen, Hungary
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.